The complex landscape of luminal breast cancer

2024/10/28 by Catrin Lutz, Hendrik A. Messal, Damir Varešlija +1 · 1 voice
Biochemistry, Genetics and Molecular Biology · Computer Science · Medicine · #Computational Drug Discovery Methods #Estrogen and related hormone effects #HER2/EGFR in Cancer Research

paper · doi:10.1530/erc-24-0201

openalex publication_date 2024/10/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15

Abstract

The breast epithelium, vital for mammary gland function, is influenced by oestrogen through the oestrogen receptor (ER) signalling pathway. Luminal breast cancer (BC), characterised by ER expression, comprises the majority of all BCs and presents significant clinical challenges due to therapy resistance and recurrence. Despite advancements in understanding luminal disease, improving long-term survival and reducing relapse of BC patients by predicting therapy efficacy and understanding resistance mechanisms remain critical challenges. This review discusses luminal BC biology, focusing on the molecular classification of primary disease, metastatic spread, and experimental models.

Citations

• Systematic identification of genomic markers of drug sensitivity in cancer cells
• A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
• Human organoids: model systems for human biology and medicine

Discussions

• Sharing the final version of our review on the complex landscape of luminal breast cancer now published with @stefanprekovic.bsky.social, @catrinlutz.bsky.social, and Hendrik. Available here: doi.org/ [bsky, 3 points, 0 comments]

Related

• Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review
• Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
• Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
• Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
• Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy